NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Instruments & Supplies · USD

Harvard Bioscience, Inc. (HBIO) Stock Analysis

Harvard Bioscience, Inc. (HBIO) is a Medical Instruments & Supplies stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

HBIO

$8.49

+$0.15 (+1.80%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HBIO with… →

HBIO Key Statistics

As of Oct 21, 2026
Trading
Open
$8.28
Previous Close
$8.34
Day's Range
8.17–8.49
52-Week Range
4.00–9.40
Volume
11.42K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.51
Valuation
Market Cap
$38.65M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
13.16
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.31
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.44
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.31
Financials (FY)
Revenue (FY)
$86.55M−8.06%
Net Income (FY)
−$56.70M
Profit marginThe share of revenue left as profit after all costs and taxes.
−11.86%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
4.55M
1-Year Return
+107.07%
Dividend and dates
Earnings Date
November 10, 2026estimated
Avg Volume
18.05K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, HBIO closed at $8.49, +107.07% over 1 year.

Harvard Bioscience, Inc. (HBIO) has a market capitalization of $38.65M.

In fiscal 2025, HBIO reported revenue of $86.55M.

HBIO Stock Return by Calendar Year

Harvard Bioscience, Inc. (HBIO) 10-year return: what $10,000 became

1 year
$10,000 $20,707
+107.07%
5 years
$10,000 $1,201
−87.99%
10 years
$10,000 $3,204
−67.96%

If you had invested $10,000 in Harvard Bioscience, Inc. (HBIO) 10 years ago, at the close on October 21, 2016, it would have been worth $3,204 at the close on October 21, 2026: −67.96% in total, −10.76% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+26.72%
2025−68.25%
2024−60.56%
2023+93.14%
2022−60.71%
2021+64.34%
2020+40.66%
2019−4.09%
2018−3.64%
2017+8.20%
2016 (partial year)+11.31%

As of October 21, 2026.

HBIO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$86.55M−$56.70M−65.5%
2024$94.14M−$12.41M−13.2%
2023$112.25M−$3.42M−3.0%
2022$113.34M−$9.52M−8.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$86.55M$49.91M$100.00K−$56.70M−65.5%
2024$94.14M$54.77M−$6.21M−$12.41M−13.2%
2023$112.25M$66.07M$1.89M−$3.42M−3.0%
2022$113.34M$60.82M−$7.17M−$9.52M−8.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

HBIO Valuation vs Medical Instruments & Supplies Median

Median of 50 stocks
MetricHBIOMedical Instruments & Supplies medianvs median
P/S ratio0.442.600.2x the median
Profit margin−11.86%1.62%13.5 pts below

Medians across 50 Medical Instruments & Supplies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Harvard Bioscience, Inc. (HBIO) at $38.65M. The company sits in the Healthcare sector, in the Medical Instruments & Supplies industry. Headcount on file is 316.

The 52-week range on file runs from $4.00 to $9.40. HBIO last closed at $8.49 on October 21, 2026. That is +$0.15 (+1.80%) against the previous close. The latest close sits 112.25% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $86.55M. That is −8.06% against the prior fiscal year, when revenue was $94.14M. The same year closed with a net loss of $56.70M. The reported profit margin is −11.86%. That is 13.5 percentage points below the Medical Instruments & Supplies median of 1.62%. Earnings per share on a trailing basis come to −2.31.

Across the 4 fiscal years on file, revenue moves from $113.34M in 2022 to $86.55M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 13.16. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.31. The price-to-sales ratio is 0.44. On price-to-sales that is 0.2 times the Medical Instruments & Supplies median of 2.6. 50 Medical Instruments & Supplies companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.51. Daily returns over the trailing 10 years annualize to a volatility of 80.41%. The trailing one-year total return is +107.07%. Measured over 10 years, that is −10.76% a year compounded.

Growth & Income

The record shows no dividend for HBIO.

2026 is still running; the total return is +26.72% year to date. Across the complete calendar years on file, 2023 returned +93.14% and 2025 returned −68.25%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Harvard Bioscience, Inc. (HBIO) operates in the Medical Instruments & Supplies industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Harvard Bioscience, Inc. HBIO $38.65M —
Intuitive Surgical, Inc. ISRG $151.25B 51.8
Becton, Dickinson and Company BDX $52.79B 45.1
Medline Inc. MDLN $47.51B 88.3

The Medical Instruments & Supplies industry average P/E ratio is 31.2x. Harvard Bioscience, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Instruments & Supplies Stocks

ISRG

Intuitive Surgical, Inc.

$151.25B

 BDX

Becton, Dickinson and Company

$52.79B

 MDLN

Medline Inc.

$47.51B

 RMD

ResMed Inc.

$34.63B

 ALC

Alcon Inc.

$32.60B

 WST

West Pharmaceutical Services, Inc.

$27.69B
View all Medical Instruments & Supplies stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Harvard Bioscience, Inc.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Visit website →